GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Cash Conversion Cycle

Firebrick Pharma (ASX:FRE) Cash Conversion Cycle : 577.09 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Firebrick Pharma's Days Sales Outstanding for the six months ended in Jun. 2024 was 0.
Firebrick Pharma's Days Inventory for the six months ended in Jun. 2024 was 1289.83.
Firebrick Pharma's Days Payable for the six months ended in Jun. 2024 was 712.74.
Therefore, Firebrick Pharma's Cash Conversion Cycle (CCC) for the six months ended in Jun. 2024 was 577.09.


Firebrick Pharma Cash Conversion Cycle Historical Data

The historical data trend for Firebrick Pharma's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Cash Conversion Cycle Chart

Firebrick Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Cash Conversion Cycle
- 72,315.63 222,467.50 2,706.76

Firebrick Pharma Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
Cash Conversion Cycle - 4,760.87 - 11.56 577.09

Competitive Comparison of Firebrick Pharma's Cash Conversion Cycle

For the Drug Manufacturers - General subindustry, Firebrick Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Firebrick Pharma's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Firebrick Pharma's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Firebrick Pharma's Cash Conversion Cycle falls into.



Firebrick Pharma Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Firebrick Pharma's Cash Conversion Cycle for the fiscal year that ended in Jun. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=1679+2305.26-1277.5
=2,706.76

Firebrick Pharma's Cash Conversion Cycle for the quarter that ended in Jun. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+1289.83-712.74
=577.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Firebrick Pharma  (ASX:FRE) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Firebrick Pharma Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Firebrick Pharma Business Description

Traded in Other Exchanges
N/A
Address
440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Firebrick Pharma Headlines

No Headlines